16 results on '"Ladon, Dariusz"'
Search Results
2. A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program
3. Unraveling facets of MECOM-associated syndrome: somatic genetic rescue, clonal hematopoiesis, and phenotype expansion
4. Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott - Aldrich Syndrome
5. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
6. TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
7. Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
8. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
9. TT52CAR19: Phase 1 Trial of CRISPR/Cas9 Edited Allogeneic CAR19 T Cells for Paediatric Relapsed/Refractory B-ALL
10. TP53mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
11. A novel human fetal liver-derived model reveals that MLL-AF4 drives a distinct fetal gene expression program in infant ALL
12. DNA methylation-based profiling for paediatric CNS tumour diagnosis and treatment: a population-based study
13. Long Terminal Repeat CRISPR-CAR-Coupled “Universal” T Cells Mediate Potent Anti-leukemic Effects
14. Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53-Mutations Using an Independent International Cohort
15. TP53Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
16. Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.